Synthesis and characterization of Rosuvastatin calcium impurity A; a HMG-CoA reductase inhibitor
- Authors
- Lee, Young Hee; Viji, Mayavan; Lee, Eunhwa; Jo, Hyeju; Yoo, Kyung; Sim, Jaeuk; Lee, Sunhwan; Lee, Kiho; Lee, Heesoon; Jung, Jae-Kyung
- Issue Date
- 28-6월-2017
- Publisher
- PERGAMON-ELSEVIER SCIENCE LTD
- Keywords
- Statins; Rosuvastatin calcium; HMG-CoA reductase inhibitor; Drug impurities; beta-Hydroxy sulfonamide
- Citation
- TETRAHEDRON LETTERS, v.58, no.26, pp.2614 - 2617
- Indexed
- SCIE
SCOPUS
- Journal Title
- TETRAHEDRON LETTERS
- Volume
- 58
- Number
- 26
- Start Page
- 2614
- End Page
- 2617
- URI
- https://scholar.korea.ac.kr/handle/2021.sw.korea/83082
- DOI
- 10.1016/j.tetlet.2017.05.075
- ISSN
- 0040-4039
- Abstract
- During the process development for multistep synthesis of Rosuvastatin calcium several impurities were obtained along with the final Rosuvastatin calcium. Out of this; synthesis of impurity A (acetone adduct) a minor impurity of Rosuvastatin calcium (3R,5S,6E)-7-[4-(4-fluorophenyl)-2-[[(2-hydroxy-2-methyl-propyl)sulfonyl(methyl)amino]-6-(1-methylethyl)-pyrimidin-5-y1]-3,5-dihydroxyheptenoicacid hemicalcium salt, is described. The synthesis of impurity A has been accomplished in 6 steps; starting from formation of beta-hydroxy sulfonamide as the key intermediate and followed by using convenient routes with overall yield of 13.5%. The target compound can be used as the reference substance of impurity of the Rosuvastatin calcium. (C) 2017 Elsevier Ltd. All rights reserved.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - College of Pharmacy > Department of Pharmaceutical Science > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.